Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced that the Galactic53 study of VILTEPSO® (generic name: viltolarsen) ? a treatment for Duchenne ...

On Wednesday, Bourla is expected to sit down with Starboard after reports early last week that the investment firm had ...

The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...

Capricor Therapeutics plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.